Omeros Corporation focuses on developing and commercializing therapeutics for various medical conditions, particularly in the areas of inflammation, pain, and blood disorders. Its lead product, Omidria, is used during cataract surgery and has established a foothold in the ophthalmology market, providing a unique competitive edge due to its dual-action mechanism.
Business Overview
Omeros generates revenue primarily through the sale of Omidria, which is priced at approximately $1,500 per treatment. The company benefits from a unique formulation that combines an analgesic and a mydriatic agent, giving it pricing power in a niche market. Additionally, the company is exploring further indications for its proprietary compounds, which could diversify revenue streams.
FDA approvals for new indications or products
Sales growth of Omidria in the U.S. and potential international markets
Partnerships or licensing agreements with larger pharmaceutical companies
Clinical trial results for pipeline products
Risk Factors
Regulatory changes affecting drug approval processes
Technological disruption in drug delivery systems
Emergence of alternative treatments for cataract surgery
Increased competition from larger pharmaceutical companies with more resources
Negative ROE indicating potential issues with profitability
High operating cash flow burn rate
Macro Sensitivity
moderate - As a biotech firm, Omeros is somewhat insulated from economic cycles; however, healthcare spending can be affected by broader economic conditions.
Rising interest rates could increase the cost of capital for Omeros, potentially impacting its ability to fund R&D and operations, although it currently has a negative debt/equity ratio.
minimal - The company is not heavily reliant on credit markets due to its low debt levels.
Profile
growth - Investors looking for high-risk, high-reward opportunities in biotech.
high - The stock has exhibited significant price volatility, as evidenced by its 1-year return of 234.9%.
Explore More
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
